Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meilleurtaux Enters Into a Definitive Agreement to Acquire Peasy, Creating the #1 Financial Services Champion for Household Finances in Belgium23.12.2025 08:00:00 EET | Press release
Meilleurtaux, a leading omnichannel financial services brokerage platform in France, Belgium, and Luxembourg backed by Silver Lake, today announced that it has entered into a definitive agreement to acquire Peasy, a leading omnichannel broker for household finances in Flanders. Together, Meilleurtaux and Peasy will form a scaled and unified platform designed to serve Belgian households across the full spectrum of their financial needs, including mortgage credit, consumer credit and insurance. This acquisition creates a national Belgian champion that combines Peasy’s local market leadership in Flanders through key brands such as Hypotheek.winkel and Verzekeringen.be, together with Meilleurtaux’s established presence in Wallonia. It represents a further milestone in the international expansion of Meilleurtaux, which first entered the Belgian market through the acquisition of MiD Finance in 2023, and supports Meilleurtaux on its continued path to becoming a leading pan-European financial
Comera Financial Holdings, Part of Abu Dhabi’s Royal Group, and SC Ventures Announce Strategic Collaboration to Explore Innovation in SME and Beyond23.12.2025 07:05:00 EET | Press release
Comera Financial Holdings, part of Abu Dhabi’s Royal Group, and SC Ventures signed an MoU announcing a strategic collaboration to jointly explore new opportunities designed to strengthen the SME segment. The initiative reflects a shared vision to advance technology-driven financial solutions that align with the UAE’s economic priorities and support sustainable development across key sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222001568/en/ Akhtar Saeed Hashmi, Managing Director & Group CEO of Comera Financial Holdings, and Alex Manson, CEO of Standard Chartered Ventures, sign an MoU announcing a strategic collaboration. (Photo: AETOSWire) Through this collaboration, Comera Financial Holdings and SCV have outlined several areas where their combined expertise can create significant value for businesses. A major focus will be on financial solutions tailored for corporates with extensive SME networks. These may in
Lattice to Showcase its Latest FPGA Technology Innovations at the International VLSID Conference23.12.2025 02:55:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming International VLSID Conference taking place January 3 – 7, 2026 in Pune, India. As part of the event, Lattice Senior Vice President of Research and Development Pravin Desale will deliver a keynote presentation exploring the market dynamics and trends that are positioning low power FPGAs at the forefront of technological advancements. Lattice will also have track sessions and panel discussions on low power FPGAs and AI from edge to cloud, and technology demonstrations with industry partners focused on advanced automotive and robotics applications. Who: Lattice Semiconductor What / When (GMT+2): Lattice Demo Showcase (Major Stall #B1), Jan 5 – 7 Keynote Jan. 5, 10:30 – 11 a.m. at Main Auditorium “Powering the Future – How Low Power FPGAs are Shaping Tomorrow’s Tech Landscape” by Pravin Desale, Head of R&D, Lattice Semiconductor Track and Panel Discussions Jan. 3,
First Cessna SkyCourier Delivered into Mexico, Expanding Air Freight Capabilities for FlexCoah22.12.2025 19:13:00 EET | Press release
The first Cessna SkyCourier in Mexico was recently delivered to cargo transportation provider FlexCoah for use by the company’s aviation subsidiary, Altair. The aircraft — a freighter variant — will expand the company’s air freight capabilities throughout the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222890759/en/ First Cessna SkyCourier delivered into Mexico, expanding air freight capabilities for FlexCoah (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Cessna SkyCourier’s combination of reliability, payload capacity and mission flexibility makes it a powerful asset for operators looking to scale their operations while maintaining cost-efficiency,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “The delivery of the Cessna SkyCourier to FlexCoah reflects the aircraft’s growing role in tran
Proudly Produced in Donegal: ProAmpac Invests in the Future of Food Board Manufacturing22.12.2025 18:34:00 EET | Press release
ProAmpac, a global leader in flexible packaging and material science, is strengthening its operational footprint with the expansion of Food Board manufacturing capabilities at its Donegal, Ireland campus. The addition of a new, purpose-built Food Board production area within the existing site reinforces ProAmpac’s commitment to innovation, efficiency, and customer service across the food packaging sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222149380/en/ Carr & Sons Smoked Salmon - ProAmpac As an extension of the existing Donegal operations, which support the pet food, food-to-go, and CPG markets, the expanded production area increases capacity and precision. A state-of-the-art guillotine system delivers cleaner cuts and consistent board quality, ensuring every sheet meets ProAmpac’s performance standards. The expanded facility area introduces several key improvements for customers: Dedicated Customer Service T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom